Propensity score matching was used to adjust for baseline differences between 124 CT-P13–treated and 124 reference infliximab-treated patients with ankylosing spondylitis who were included in the Korean College of Rheumatology Biologics registry.

Over a follow-up period of up to 4 years, treatment duration and retention rate did not significantly differ between CT-P13 and reference infliximab, efficacy assessments were generally similar between groups, and both treatments were well tolerated.

These real-world, long-term findings provide robust evidence of the comparability of CT-P13 and reference infliximab, supporting the routine clinical use of CT-P13 in patients with ankylosing spondylitis.